Skip to main content
Feiran Liu on Muck Rack

Feiran Liu

As seen in: Color Research & Application, Wiley Online Library, Canadian Journal of Infectious Diseases & Medical Microbiology, Dove Medical Press, Reproductive BioMedicine Online, EJSO - European Journal of Surgical Oncology

Get in touch with Feiran

Contact Feiran, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Record‐High Performance Hyperfluorescent OLEDs Achieved via Electronic Structure Control of Chlorine‐Diversified MR‐TADF Emitters

|
By Taehwan Lee, Junki Ochi, Feiran Liu, Shigetada Uemura
| Wiley Online Library Verified
1 Introduction Organic light-emitting diodes (OLEDs) have achieved remarkable progress through the evolution of diverse emitter systems, from fluorescence and heavy-metal phosphorescence to purely organic thermally activated delayed fluorescence (TADF) [1-3]. Among them, multiple-resonance (MR)-type TADF materials have emerged over the past decade as a particularly promising class of emitters for next-generation displays [4-8].
Open in Who Shared Issue with article?

Naphthalimide‐Based Dyed Long Fluorescent Lifetime Probe for Lipid Droplet Viscosity Mapping in Non‐Alcoholic Fatty Liver Disease

|
By Yifan Liu, Feiran Liu, Tong Wu, Fei Yuan
| Wiley Online Library Verified
Conflicts of Interest The authors declare no conflicts of interest. Data Availability Statement The data that support the findings of this study are available in the supplementary material of this article.
Open in Who Shared Issue with article?

Secondary cytoreductive surgery followed by olaparib tablets as maintenance therapy in patients with BRCA mutated recurrent ovarian cancer: A multi-center retrospective study

|
By Dong Yang, Yanbin Zhang, Ping Gong, Sijia Ren, Feiran Liu, Chao Wang, Xinxin Zhao, Wenpei Bai, Yale Gan, Renzi Liu
| EJSO - European Journal of Surgical Oncology Verified
To evaluate the effect of secondary cytoreductive surgery (SeCRS) followed by platinum-based chemotherapy (PBC) and olaparib tablets as maintenance therapy in patients with BRCA mutated recurrent epithelial ovarian cancer. This was a retrospective study of a prospective database. We collected information on 623 patients diagnosed with BRCA mutated recurrent epithelial ovarian cancer, all of whom underwent SeCRS followed by PBC in combination with or without olaparib.
Open in Who Shared Issue with article?
See all 7 licensed articles (8 Total)